Identification of novel myelin repair drugs by modulation of oligodendroglial differentiation competence.

ABSTRACT:

Background

In multiple sclerosis loss of myelin and oligodendrocytes impairs saltatory signal transduction and leads to neuronal loss and functional deficits. Limited capacity of oligodendroglial precursor cells to differentiate into mature cells is the main reason for inefficient myelin repair in the central nervous system. Drug repurposing constitutes a powerful approach for identification of pharmacological compounds promoting this process.

Methods

A phenotypic compound screening using the subcellular distribution of a potent inhibitor of oligodendroglial cell differentiation, namely p57kip2, as differentiation competence marker was conducted. Hit compounds were validated in terms of their impact on developmental cell differentiation and myelination using both rat and hum

SUBMITTER: Manousi A 

PROVIDER: S-EPMC7970057 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature